IFA treatment facilitated host immune clearance of hypervirulent <i>K</i>. <i>pneumoniae</i> by targeting capsule. by Tingting Wang (123983)

IFA effectively limited bacterial dissemination and protected mice from lethal hypervirulent <i>K</i>. <i>pneumoniae</i> pneumonia. by Tingting Wang (123983)

Raw data underlying the findings in this study. by Andrew Mvula (20161161)

“…The relative bone density significantly decreased as standard length and condition factor (<i>K</i>) increased in both sexes. …”

Safranin O fast green staining results of cartilage tissue in different groups of rat PTOA (A: normal group, B: mild PTOA group, C: severe PTOA group). by Peng-fei Han (694841)

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Socio-demographic characteristics of the population. by Sara Saleh (6733619)

Subjects:

Knowledge, attitude and practice scores in the general population and according to regions. by Sara Saleh (6733619)

Subjects:

Side effects of vaccination that affected participants’ children. by Sara Saleh (6733619)

Subjects:

Bivariate analysis of sociodemographic and other factors associated with the knowledge scores. by Sara Saleh (6733619)

Subjects:

Bivariate analysis of sociodemographic and other factors associated with the attitude scores. by Sara Saleh (6733619)

Subjects:

Multivariate analysis of sociodemographic and other factors associated with the KAP scores. by Sara Saleh (6733619)

Subjects:

Participants’ perceived ways to boost children’s immune system other than vaccination. by Sara Saleh (6733619)

Subjects:

Bivariate analysis of sociodemographic and other factors associated with the practice scores. by Sara Saleh (6733619)

Subjects: